Sarepta Extends $700M Debt to 2030, Adds Private Placement Amid Elevidys Uncertainty

Sarepta Therapeutics has reached an agreement to extend the maturity on $700 million of its $1.1 billion in convertible debt from 2027 to 2030, improving the company's long-term financial flexibility412.

As part of the deal, Sarepta will exchange $700 million of existing convertible notes for new notes worth $602 million and company shares, plus $123.3 million in cash3.

The extension is taking place amid ongoing uncertainty regarding Sarepta's flagship gene therapy, Elevidys4.

Sarepta has also initiated a private placement to further strengthen its capital position4.

Sources:

1. https://www.gurufocus.com/news/3073263/sarepta-therapeutics-announces-strategic-exchange-of-convertible-notes-srpt-stock-news

2. https://www.tipranks.com/news/ratings/sarepta-therapeutics-hold-rating-amid-debt-maturity-extension-and-strategic-execution-focus-ratings

3. https://www.stockinsights.ai/us/SRPT/8-K/capital-structure-changes-20250821-73e

4. https://www.fiercepharma.com/pharma/sarepta-extends-700m-debt-2030-adds-private-placement-amid-elevidys-uncertainty